Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Excelsior Medical Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$3,336 Mil.
Excelsior Medical Co's quarterly Ending Cash Position
increased
from Dec. 2025 (NT$2,847 Mil) to Mar. 2026 (NT$3,078 Mil) and
increased
from Mar. 2026 (NT$3,078 Mil) to Jun. 2026 (NT$3,336 Mil).
Excelsior Medical Co's annual Ending Cash Position
increased
from Dec. 2023 (NT$2,615 Mil) to Dec. 2024 (NT$4,189 Mil) but then
declined
from Dec. 2024 (NT$4,189 Mil) to Dec. 2025 (NT$2,847 Mil).
Excelsior Medical Co Ending Cash Position Related Terms
Excelsior Medical Co Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Excelsior Medical Co's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Excelsior Medical Co Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Excelsior Medical Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of NT$3,336 Mil mean?
Excelsior Medical Co (TPE:4104) has a Ending Cash Position of NT$3,336 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Excelsior Medical Co and its competitors.
Is Excelsior Medical Co's Ending Cash Position too high?
Excelsior Medical Co's current Ending Cash Position is NT$3,336 Mil. Overall, Excelsior Medical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Excelsior Medical Co's Ending Cash Position compare to MCK and COR?
Excelsior Medical Co's Ending Cash Position of NT$3,336 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Distribution company?
A good Ending Cash Position depends on the Medical Distribution industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Excelsior Medical Co and its competitors. Excelsior Medical Co's current Ending Cash Position is NT$3,336 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Medical Co (TPE:4104) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$86.47, compared to a current price of NT$71.10 — trading 17.8% below its estimated fair value. The current Ending Cash Position is NT$3,336 Mil. Excelsior Medical Co's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Excelsior Medical Co (TPE:4104), the current Ending Cash Position is NT$3,336 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Medical Co (TPE:4104) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Medical Co stock appears to be undervalued.
The current stock price of NT$71.10 is trading 17.8% below its estimated GF Value™ of NT$86.47.
GuruFocus considers Excelsior Medical Co to be Modestly Undervalued.
Key valuation signals for TPE:4104:
Ending Cash Position: NT$3,336 Mil
GF Value™: NT$86.47 vs. price of NT$71.10 (17.8% below fair value)
No single metric tells the full story. See the TPE:4104 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Medical Co Ltd is engaged in the sale of medical supplies and medicines, home medical devices, and medical equipment with brand names of local and foreign manufacturers. Its product offerings include Fasflo hollow fiber dialyzer, Renabio sodium chloride injection, acid concentrates, Sunder blood purification tubing set, JMS blood bags, etc. The Group's reportable segments include Excelsior, Dynamic, Arich, and Others. Maximum revenue is generated from the Excelsior segment. Geographically, it derives key revenue from Taiwan and also has a presence in Hong Kong, China, the Philippines, Malaysia, and Indonesia.
85GF Score
Get the complete analysis for TPE:4104
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4104 has been successfully added to your 
